Royal Bank Of Canada Mereo Biopharma Group PLC Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.3 - $4.05 $66 - $117	-29 Reduced 50.88%	28 $0
Q4 2023 Feb 14, 2024	BUY	$1.19 - $2.42 $67 - $137	57 New	57 $0
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $11 - $21	-15 Reduced 51.72%	14 $0
Q1 2023 May 15, 2023	SELL	$0.71 - $1.22 $0 - $1	-1 Reduced 3.33%	29 $0
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $107 - $217	-215 Reduced 87.76%	30 $0
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $12 - $25	15 Added 6.52%	245 $0
Q2 2022 Aug 15, 2022	BUY	$0.33 - $1.69 $75 - $388	230 New	230 $0
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $11,325 - $19,425	-7,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.2 - $3.17 $16,445 - $23,695	7,475 Added 29900.0%	7,500 $18,000
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $73 - $102	25 New	25 $0

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.